This is a working overview of c-Met receptor, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-07-30. Anything still debated is marked as such rather than presented as settled.
Dihexa is a synthetic peptidomimetic derived from angiotensin IV, a naturally occurring peptide fragment. It was created as a research compound to explore central nervous system signaling rather than as an approved therapeutic. Early work described it as a small, orally available molecule in rodent studies. Its structure combines tyrosine, isoleucine, and aminohexanoic acid components with a hexanoic acid cap. The compound is commonly referred to by the research code PNB-0408.
Development of dihexa followed from studies on angiotensin IV analogs and their effects on learning and memory. Researchers sought compounds with improved metabolic stability and brain penetration compared with natural peptides. In preclinical reports, dihexa was associated with changes in synaptic connectivity and performance on spatial tasks. These findings generated interest in its potential as a cognitive research tool. The work remains largely preclinical, and independent replication has been limited.
Development of dihexa has been linked to academic research on synaptogenesis, the formation of new synapses. Preclinical studies in rodents have examined its effects on learning and memory tasks. These studies are often cited in discussions about cognitive enhancement, but they do not establish safety or efficacy in humans. The compound's patent and commercial history is limited, and it is not widely available through pharmaceutical channels. Most information comes from animal models and in vitro experiments. Researchers continue to explore its basic biology rather than clinical applications.
Dihexa is not approved for human use in the United States or the European Union. It is commonly sold as a research chemical, a category that may not require the same regulatory review as medicines. Buyers should note that product labels may lack independent verification of identity or purity. The legal status can vary by country, and importation may be restricted. Reliable information about sourcing and quality is often scarce. Scientific publications typically use synthesized material from laboratories rather than commercial consumer products.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic angiotensin IV analog | Peptidomimetic |
| Appearance | White to off-white powder | Lyophilized solid |
| Solubility | Soluble in DMSO; limited in water | Typical for small peptides |
| Storage | -20 °C, desiccated | Protect from light and moisture |
| Analytical method | HPLC with UV detection | Purity and identity checks |
Regulatory treatment varies by country. Dihexa does not appear in major pharmacopeias as a licensed therapeutic substance. Suppliers may use labels such as research use only or not for human consumption. Such labels reflect legal and quality-control boundaries rather than evidence of clinical benefit. Importation, possession, and sale can be restricted depending on local laws, and enforcement focuses on claims, distribution channels, and product categories. These rules can change, and they differ from rules for approved medicines.
Dihexa is a synthetic peptide studied in preclinical neuroscience. It is often described as an angiotensin IV analog or derivative. The compound also appears under research codes such as PNB-0408 and N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. It is not an approved drug, and it is not a conventional vitamin or nutrient. In many jurisdictions, material sold as dihexa is handled as a research chemical rather than a medicine or supplement. This classification affects how the material is labeled and distributed.
Chemically, dihexa is a short peptide-like molecule with nonstandard components. Its structure includes tyrosine and isoleucine residues linked to a hexanoic acid group and an aminohexanoic amide segment. This design distinguishes it from endogenous angiotensin IV, though the two are discussed together because of shared origins. Published summaries classify it as a small synthetic peptide with lipophilic features that may influence how it crosses biological barriers in experimental systems. Exact conformational details depend on the specific salt or free base form.
The compound has been examined in animal models for effects on learning, memory, and synaptic connectivity. Some reports describe increased dendritic spine density and improved performance on certain behavioral tasks after administration in rodents. These findings are often cited in discussions of nootropic research peptides, but replication across independent laboratories remains limited. The absence of published phase 1 or phase 2 clinical trial data makes it difficult to assess safety, effective routes, or long-term outcomes in humans. Consequently, claims about cognitive benefits in people remain speculative.
Dihexa is not approved as a medicine in major regulatory jurisdictions. It is commonly sold as a research chemical for laboratory use, though such products may not be standardized or independently verified. Scientific literature on dihexa includes in vitro assays, rodent studies, and reviews that discuss its proposed mechanism. The distinction between peer-reviewed findings and commercial promotion is important when evaluating available information. Open questions include its precise binding interactions, pharmacokinetics, and whether animal results translate to human biology.
=== Role in apoptosis === Cytochrome c was also discovered in 1996 by Xiaodong Wang to have an intermediate role in apoptosis, a controlled form of cell death used to kill cells in the process of development or in response to infection or DNA damage. Cytochrome c binds to cardiolipin in the inner mitochondrial membrane, thus anchoring its presence and keeping it from releasing out of the mitochondria and initiating apoptosis. While the initial attraction between cardiolipin and cytochrome c is electrostatic due to the extreme positive charge on cytochrome c, the final interaction is hydrophobic, where a hydrophobic tail from cardiolipin inserts itself into the hydrophobic portion of cytochrome c. During the early phase of apoptosis, mitochondrial ROS production is stimulated, and cardiolipin is oxidized by a peroxidase function of the cardiolipin–cytochrome c complex. The hemoprotein is then detached from the mitochondrial inner membrane and can be extruded into the soluble cytoplasm through pores in the outer membrane. The sustained elevation in calcium levels precedes cyt c release from the mitochondria. The release of small amounts of cyt c leads to an interaction with the IP3 receptor (IP3R) on the endoplasmic reticulum (ER), causing ER calcium release. The overall increase in calcium triggers a massive release of cyt c, which then acts in the positive feedback loop to maintain ER calcium release through the IP3Rs. This explains how the ER calcium release can reach cytotoxic levels. This release of cytochrome c in turn activates caspase 9, a cysteine protease.
It makes determinations about what objects to prioritize based on what is especially important to Congress or potentially interesting for the public. The 15 million digitized items represent less than 10% of the library's total 160-million-item collection. The library has chosen not to participate in other digital library projects such as Google Books and the Digital Public Library of America, although it has supported the Internet Archive project.
A breakthrough in understanding the flow of blood through the heart and body came with the publication of De Motu Cordis (1628) by the English physician William Harvey. Harvey's book completely describes the systemic circulation and the mechanical force of the heart, leading to an overhaul of the Galenic doctrines. Otto Frank (1865–1944) was a German physiologist; among his many published works are detailed studies of this important heart relationship. Ernest Starling (1866–1927) was an important English physiologist who also studied the heart. Although they worked largely independently, their combined efforts and similar conclusions have been recognized in the name "Frank–Starling mechanism". Although Purkinje fibers and the bundle of His were discovered as early as the 19th century, their specific role in the electrical conduction system of the heart remained unknown until Sunao Tawara published his monograph, titled Das Reizleitungssystem des Säugetierherzens, in 1906. Tawara's discovery of the atrioventricular node prompted Arthur Keith and Martin Flack to look for similar structures in the heart, leading to their discovery of the sinoatrial node several months later. These structures form the anatomical basis of the electrocardiogram, whose inventor, Willem Einthoven, was awarded the Nobel Prize in Medicine or Physiology in 1924. The first heart transplant in a human ever performed was by James Hardy in 1964, using a chimpanzee heart, but the patient died within 2 hours.
== Secondary metabolites == A variety of organisms including bacteria, fungi, and plants, produce small molecule secondary metabolites also known as natural products, which play a role in cell signaling, pigmentation and in defense against predation. Secondary metabolites are a rich source of biologically active compounds and hence are often used as research tools and leads for drug discovery. Examples of secondary metabolites include:
Sources: en.wikipedia.org
====== Glycerin ====== Glycerin (often called vegetable glycerin, or VG) was long thought to be a safe option. However, the carcinogen formaldehyde is known as an impurity found in propylene glycol and glycerol vapor degradation.
Anders Ericsson of Florida State University did not believe that sufficient evidence existed to suggest that the skills of Price and another documented case, Brad Williams, needed additional explanation: "Our work has pretty much concluded that differences in memory don't seem to be the result of innate differences, but more the kinds of skills that are developed." As the condition has become better known, more people claiming to have hyperthymestic abilities have emerged. In the aftermath of the 2006 Neurocase publication alone, more than 200 people contacted McGaugh; however, only a handful of cases were determined to be actual cases of hyperthymesia. The second verified case was Brad Williams, the third was Rick Baron, and in 2009, Bob Petrella became the fourth person diagnosed with hyperthymestic syndrome. The U.S. television program 60 Minutes featured actress Marilu Henner in 2010 for her superior autobiographical memory ability. Henner claimed to remember almost every day of her life since age 11. The show was initially pitched as a story featuring hyperthymestic violinist Louise Owen, but the reporter Lesley Stahl volunteered her friend Henner as having a similar ability. In 2012, reports emerged of H.K. Derryberry, a blind 20-year-old man who could clearly recall every day of the last nine years of his life. Derryberry had been born at 27 weeks, weighing just over 2 pounds (0.91 kg) and was in neonatal intensive care for 96 days. A brain hemorrhage was the likely cause of cerebral palsy, and his premature birth brought congenital blindness.
2) Order 1993 (S.I. 1993/1821) Occupational Pension Schemes (Preservation of Benefit) Amendment Regulations 1993 (S.I. 1993/1822) Offshore Safety (Repeals and Modifications) Regulations 1993 (S.I. 1993/1823) Export of Goods (Control) (Amendment No. 4) Order 1993 (S.I. 1993/1825) Financial Services (Disclosure of Information) (Designated Authorities) (No. 7) Order 1993 (S.I. 1993/1826) Church of England (Legal Aid) Rules 1993 (S.I. 1993/1840) Diocesan Chancellorship Regulations 1993 (S.I. 1993/1841) Ecclesiastical Judges and Legal Officers (Fees) Order 1993 (S.I. 1993/1842) Legal Officers (Annual Fees) Order 1993 (S.I. 1993/1843) Parochial Fees Order 1993 (S.I. 1993/1844) Local Government Superannuation (Investments) Regulations 1993 (S.I. 1993/1848) Highways (Traffic Calming) Regulations 1993 (S.I. 1993/1849) Education (Mandatory Awards) Regulations 1993 (S.I. 1993/1850) Social Security (Invalid Care Allowance) Amendment (No. 2) Regulations 1993 (S.I. 1993/1851) Assisted Areas Order 1993 (S.I. 1993/1877) Seed Potatoes (Amendment) Regulations 1993 (S.I. 1993/1878) Public Telecommunication System Designation (City of London Telecommunications Ltd) Order 1993 (S.I. 1993/1879) Public Telecommunication System Designation (Ionica L3 Ltd) Order 1993 (S.I. 1993/1880) Companies Act 1989 (Recognised Supervisory Bodies) (Periodical Fees) Regulations 1993 (S.I. 1993/1881) Learning for Work (Scottish Enterprise and Highlands and Islands Enterprise Programmes) Order 1993 (S.I. 1993/1882) Norway Lobsters (Prohibition of Method of Fishing) Order 1993 (S.I.
Ca(OH)2 + x/8 S8 → CaSx + by-products (S2O2−3, SO2−3, SO2−4) as reported in a document of the US Department of Agriculture (USDA). This reaction is poorly understood because it is vague and involves the reduction of elemental sulfur, and no reductant appears in the equation, while sulfur oxidation products are also mentioned. The initial pH of the solution imposed by poorly soluble hydrated lime is alkaline (pH = 12.5) while the final pH is in the range 11–12, typical for sulfides, which are also strong bases. When the hydrolysis of calcium sulfide is taken into account, the individual reactions for each of the by-products are:
=== Medical === Karl Koller's groundbreaking discovery of cocaine as a local anesthetic is regarded as the second most significant advance in the history of anesthesia. Although cocaine was once widely preferred for topical anesthesia, the search for replacement agents intensified due to rising costs, strict regulations, and its habit-forming potential. Cocaine is not included on the WHO Model List of Essential Medicines; the list formally excludes "cocaine and its combinations" as therapeutic alternatives to ophthalmological preparations. The US Drug Enforcement Administration (DEA) classifies cocaine as a Schedule II drug, recognizing its high potential for abuse but still permitting its limited use for medical purposes. However, current pharmacoepidemiological trends suggest that cocaine may soon reach the point where, in practical terms, it is no longer used medically in health care as a Schedule II substance. As physician boards—but not pharmacy boards—continue to assess knowledge of licit cocaine, attention may shift toward drugs with more contemporary medical use. Cocaine is rarely prescribed in modern medicine due to its high potential for abuse and significant risk of adverse effects; its use is almost exclusively limited to health facilities for specific diagnostic procedures or surgeries.
Sources: en.wikipedia.org
For example, if it is predicted that the transition state structure has a build-up of negative charge relative to the ground state structure, then electron-donating groups would be expected to increase the rate of the reaction. Other LFER scales have been developed. Steric and polar effects are analyzed through Taft Parameters. Changing the solvent instead of the reactant can provide insight into changes in charge during the reaction. The Grunwald-Winstein Plot provides quantitative insight into these effects.
== Research == Later, nelotanserin was repurposed for the treatment of Lewy body dementia (LBD) by Axovant Sciences (now Sio Gene Therapies). In late 2018, the company announced that while nelotanserin was generally well-tolerated by LBD patients in a small Phase 2 clinical trial for the treatment of REM sleep behavior disorder (RBD) and there were positive indications on some secondary trial outcomes such as sleep diaries and some polysomnogram sleep parameters, the drug failed to meet its primary endpoint of reducing the frequency of RBD episodes and would be discontinued.
He later co-founded the Trinity Broadcasting Network with Paul and Jan Crouch, but left after a short partnership due to disagreements, eventually establishing his own ministry, PTL (Praise The Lord), and the PTL Satellite Network. Returning to televangelism in 2003, Bakker now hosts The Jim Bakker Show with a focus on apocalyptic themes and survivalist products, while distancing himself from his earlier prosperity gospel teachings. His later years have included controversial claims, such as predicting major events and promoting unproven supplements, which drew legal action and criticism during the COVID-19 pandemic. Bakker has written several books, including I Was Wrong and Time Has Come: How to Prepare Now for Epic Events Ahead.
==== Microparticle and nanoparticle synthesis ==== Advanced particles and particle-based materials, such as polymer particles, microcapsules, nanocrystals, and photonic crystal clusters or beads can be synthesized with the assistance of droplet-based microfluidics. Nanoparticles, such as colloidal CdS and CdS/CdSe core-shell nanoparticles, can also be synthesized through multiple steps on a millisecond time scale in a microfluidic droplet-based system. Nanoparticles, microparticles and colloidal clusters in microfluidic devices are useful for functions such as drug delivery. The first particles incorporated in droplet-based systems were silica gels in the micrometer size range in order to test their applications in the manufacturing of displays and optical coatings. Mixing solid particles with aqueous microdroplets requires changes to microfluidic channels such as additional reagent mixes and choice of specific materials such as silica or polymers that do not interfere with the channels and any bioactive substances the droplets contain. The synthesis of copolymers requires milling macroscopic molecules to microparticles with porous, irregular surfaces using organic solvents and emulsification techniques. These droplets preloaded with microparticles can also be quickly processed using UV irradiation. Characterization of these microparticles and nanoparticles involves microimaging for analyzing the structure and the identification of the macroscopic material being milled.
Sources: en.wikipedia.org
Dihexa is a synthetic peptidomimetic related to angiotensin IV. It is studied in preclinical research for effects on synaptic signaling and cognition. It is not an approved medication.
No major drug regulatory agency has approved dihexa for human use. Published human clinical trials are absent, so its safety and efficacy are not established. It is commonly sold for laboratory research only.
It was developed from research on angiotensin IV analogs and peptide stability. The goal was to find compounds with better brain penetration and metabolic resistance. Early studies used rodent models rather than human participants.
Dihexa is a synthetic peptide investigated in preclinical research. It is often classified as an angiotensin IV analog or an HGF mimetic. It is not an approved medicine.